Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kymera Therapeutics
Biotech
Kymera cuts lymphoma med that performed as expected in phase 1
The targeted IRAK4 protein degrader KT-413 did exactly what it was supposed to in an phase 1 trial, but Kymera is jettisoning the program.
Annalee Armstrong
Nov 2, 2023 9:30am
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
May 26, 2023 9:30am
Sanofi backs protein degrader after glimpse of clinical efficacy
Dec 14, 2022 7:00am
Earnings arrive after dreadful 6 months, but readouts offer hope
Jul 18, 2022 9:42am
Kymera’s protein degrader shows potential to boost I-O
Nov 24, 2021 9:00am
Don't blink: PAQ gobbles up $30M series A to ink autophagy era
Jul 15, 2021 6:00am